Prophylaxis

View All Members
Mr. Site Admin
Key Publications

Publications

April 24, 2017

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia

Authors
Carcao MD, Avila L, Leissinger C, Blanchette VS, Aledort L; Factor Utilization Expert Working Group on behalf of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators.
Citation
Haemophilia 2017; 23 (5) : e444 - e447
View Publication
April 21, 2017

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia

Authors
Carcao M, Avila L, Leissinger C, Blanchette VS, and Aledort LM on behalf of the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators
Citation
Haemophilia 2017; 23 (5): e447 - e450
View Publication
December 3, 2015

Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors)

Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators.
Citation
Blood 2015; 126: 3535
View Publication
June 20, 2015

Prophylaxis practices in children and adults with inhibitors

The XXV Congress of the International Society on Thrombosis and Haemostasis (June 20 - 25, 2015 – Toronto, Canada)
Authors
Carcao M, Avila M, Aledort L, Leissinger C on behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators
Citation
July 1, 2012

Tertiary prophylaxis in adults: What is the rationale?

Authors
Gringeri A, Lambert T, Street A, and Aledort L. on behalf of the Adolescent/Adult Prophylaxis Study Group of the International Prophylaxis Study Group.
Citation
Haemophilia 2012 Sept; 18 (5): 722-728
View Publication
February 22, 2012

Why should we Care about Quality of Life in Hemophilia?

Authors
Aledort L, Bullinger M, von Mackensen S, Wasserman J, and Young NL. on behalf of the Health Related Quality of Life Expert Working Group of the International Prophylaxis Study Group.
Citation
Haemophilia 2012; May 18 (3) : e154 – e157.
View Publication
September 10, 2007

The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) Symposium.

Authors
Feldman BM, Aledort L, Bullinger M, Delaney FM, Doria AS, Funk S, Giangrande P, Lundin B, Manco-Johnson M, Miners A, Scriba PC, Srivastava A, Schramm W and Blanchette VS.
Citation
Haemophilia 2007 Nov; 13 (6): 745-749.
View Publication
March 4, 2006

Are randomized clinical trials the only truth? Not always

Authors
Aledort L, Ljung R, and Blanchette V on behalf of the International Prophylaxis Study Group (IPSG)
Citation
Journal of Thrombosis and Haemostasis 2006 Mar; 4 (3): 503 - 504.